

(51) International Patent Classification:
A61K 39/00 (2006.01)(21) International Application Number:
PCT/US2021/045062(22) International Filing Date:
06 August 2021 (06.08.2021)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
63/062,919 07 August 2020 (07.08.2020) US(71) Applicant: **OTHAIR PROTHENA LIMITED** [IE/IE];
77 Sir John Rogerson's Quay, Block C, Grand Canal Dock-
lands, Dublin 2, D02 VK60 (IE).

(72) Inventors; and

(71) Applicants: **BARBOUR, Robin** [US/US]; 250 Normandy
Lane, Walnut Creek, CA 94598 (US). **KINNEY, Gene**
[US/US]; 2800 S. Ocean Blvd., Unit 14L/M, Boca Raton,
FL 33432 (US). **ZAGO, Wagner** [US/US]; 1291 Crestview
Drive, San Carlos, CA 94070 (US).(74) Agent: **GATTARI, Patrick, G.**; McDonnell Boehnen Hul-
bert & Berghoff LLP, 300 South Wacker Drive, Chicago,
IL 60606 (US).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

FIG. 3



(57) **Abstract:** The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A β , Abe-ta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A β and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting prop-agation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A β) peptide and a tau peptide and an alpha-synuclein peptide.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*